Survivin

A novel target for indomethacin-induced gastric injury

Shiun Kwei Chiou, Tetsuya Tanigawa, Tomohiko Akahoshi, Basim Abdelkarim, Michael K. Jones, Andrzej S. Tarnawski

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Background & Aims: Nonsteroidal anti-inflammatory drugs (NSAIDs) cause gastrointestinal erosions and ulcers. Apoptosis is one of the mechanisms. The role of survivin, an antiapoptosis protein, in NSAID-induced gastric injury is unknown. We examined the role of survivin in NSAID-induced gastric mucosal and gastric cell injury. Methods: We examined: (1) the effects of indomethacin (nonselective NSAID), celecoxib and NS-398 (cyclooxygenase [COX]-2-selective NSAIDs), SC-560 (a COX-1-selective NSAID), and SC-560 plus celecoxib on survivin expression and extent of injury in rat gastric mucosa; (2) the effects of indomethacin, NS-398, SC-560, and SC-560 plus NS-398 on survivin expression and injury in gastric epithelial (RGM-1) cells; and (3) the effects of survivin suppression with small interfering RNA (siRNA) on RGM-1 cell integrity at baseline and following indomethacin injury. Results: Indomethacin treatment dose-dependently reduced survivin protein levels and caused severe injury of gastric mucosa and RGM-1 cells. Suppression of survivin expression with siRNA in RGM-1 cells caused cell damage and increased susceptibility to injury by indomethacin. Celecoxib treatment caused exfoliation of the mucosal surface epithelium, but neither caused deep erosions or altered survivin expression. Neither NS-398 nor SC-560 treatment altered survivin levels or produced injury in vivo or in vitro. COX-1 and COX-2 inhibitor combination caused injury in vivo and in vitro but did not decrease survivin expression. Conclusions: (1) Indomethacin, but not selective COX-1 or COX-2 inhibitors alone or in combination, reduces survivin expression in gastric mucosal cells and (2) significant reduction of survivin precedes greater severity of gastric injury.

Original languageEnglish
Pages (from-to)63-73
Number of pages11
JournalGastroenterology
Volume128
Issue number1
DOIs
Publication statusPublished - Jan 1 2005
Externally publishedYes

Fingerprint

Indomethacin
Stomach
Celecoxib
Wounds and Injuries
Anti-Inflammatory Agents
Gastrointestinal Agents
Cyclooxygenase 1
Cyclooxygenase 2 Inhibitors
Gastric Mucosa
Small Interfering RNA
Pharmaceutical Preparations
Cyclooxygenase 2
Ulcer
Proteins
Epithelium
SC 560
Apoptosis
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Chiou, S. K., Tanigawa, T., Akahoshi, T., Abdelkarim, B., Jones, M. K., & Tarnawski, A. S. (2005). Survivin: A novel target for indomethacin-induced gastric injury. Gastroenterology, 128(1), 63-73. https://doi.org/10.1053/j.gastro.2004.10.008

Survivin : A novel target for indomethacin-induced gastric injury. / Chiou, Shiun Kwei; Tanigawa, Tetsuya; Akahoshi, Tomohiko; Abdelkarim, Basim; Jones, Michael K.; Tarnawski, Andrzej S.

In: Gastroenterology, Vol. 128, No. 1, 01.01.2005, p. 63-73.

Research output: Contribution to journalArticle

Chiou, SK, Tanigawa, T, Akahoshi, T, Abdelkarim, B, Jones, MK & Tarnawski, AS 2005, 'Survivin: A novel target for indomethacin-induced gastric injury', Gastroenterology, vol. 128, no. 1, pp. 63-73. https://doi.org/10.1053/j.gastro.2004.10.008
Chiou, Shiun Kwei ; Tanigawa, Tetsuya ; Akahoshi, Tomohiko ; Abdelkarim, Basim ; Jones, Michael K. ; Tarnawski, Andrzej S. / Survivin : A novel target for indomethacin-induced gastric injury. In: Gastroenterology. 2005 ; Vol. 128, No. 1. pp. 63-73.
@article{997004c661234a2ab0ac48d01d357e81,
title = "Survivin: A novel target for indomethacin-induced gastric injury",
abstract = "Background & Aims: Nonsteroidal anti-inflammatory drugs (NSAIDs) cause gastrointestinal erosions and ulcers. Apoptosis is one of the mechanisms. The role of survivin, an antiapoptosis protein, in NSAID-induced gastric injury is unknown. We examined the role of survivin in NSAID-induced gastric mucosal and gastric cell injury. Methods: We examined: (1) the effects of indomethacin (nonselective NSAID), celecoxib and NS-398 (cyclooxygenase [COX]-2-selective NSAIDs), SC-560 (a COX-1-selective NSAID), and SC-560 plus celecoxib on survivin expression and extent of injury in rat gastric mucosa; (2) the effects of indomethacin, NS-398, SC-560, and SC-560 plus NS-398 on survivin expression and injury in gastric epithelial (RGM-1) cells; and (3) the effects of survivin suppression with small interfering RNA (siRNA) on RGM-1 cell integrity at baseline and following indomethacin injury. Results: Indomethacin treatment dose-dependently reduced survivin protein levels and caused severe injury of gastric mucosa and RGM-1 cells. Suppression of survivin expression with siRNA in RGM-1 cells caused cell damage and increased susceptibility to injury by indomethacin. Celecoxib treatment caused exfoliation of the mucosal surface epithelium, but neither caused deep erosions or altered survivin expression. Neither NS-398 nor SC-560 treatment altered survivin levels or produced injury in vivo or in vitro. COX-1 and COX-2 inhibitor combination caused injury in vivo and in vitro but did not decrease survivin expression. Conclusions: (1) Indomethacin, but not selective COX-1 or COX-2 inhibitors alone or in combination, reduces survivin expression in gastric mucosal cells and (2) significant reduction of survivin precedes greater severity of gastric injury.",
author = "Chiou, {Shiun Kwei} and Tetsuya Tanigawa and Tomohiko Akahoshi and Basim Abdelkarim and Jones, {Michael K.} and Tarnawski, {Andrzej S.}",
year = "2005",
month = "1",
day = "1",
doi = "10.1053/j.gastro.2004.10.008",
language = "English",
volume = "128",
pages = "63--73",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Survivin

T2 - A novel target for indomethacin-induced gastric injury

AU - Chiou, Shiun Kwei

AU - Tanigawa, Tetsuya

AU - Akahoshi, Tomohiko

AU - Abdelkarim, Basim

AU - Jones, Michael K.

AU - Tarnawski, Andrzej S.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Background & Aims: Nonsteroidal anti-inflammatory drugs (NSAIDs) cause gastrointestinal erosions and ulcers. Apoptosis is one of the mechanisms. The role of survivin, an antiapoptosis protein, in NSAID-induced gastric injury is unknown. We examined the role of survivin in NSAID-induced gastric mucosal and gastric cell injury. Methods: We examined: (1) the effects of indomethacin (nonselective NSAID), celecoxib and NS-398 (cyclooxygenase [COX]-2-selective NSAIDs), SC-560 (a COX-1-selective NSAID), and SC-560 plus celecoxib on survivin expression and extent of injury in rat gastric mucosa; (2) the effects of indomethacin, NS-398, SC-560, and SC-560 plus NS-398 on survivin expression and injury in gastric epithelial (RGM-1) cells; and (3) the effects of survivin suppression with small interfering RNA (siRNA) on RGM-1 cell integrity at baseline and following indomethacin injury. Results: Indomethacin treatment dose-dependently reduced survivin protein levels and caused severe injury of gastric mucosa and RGM-1 cells. Suppression of survivin expression with siRNA in RGM-1 cells caused cell damage and increased susceptibility to injury by indomethacin. Celecoxib treatment caused exfoliation of the mucosal surface epithelium, but neither caused deep erosions or altered survivin expression. Neither NS-398 nor SC-560 treatment altered survivin levels or produced injury in vivo or in vitro. COX-1 and COX-2 inhibitor combination caused injury in vivo and in vitro but did not decrease survivin expression. Conclusions: (1) Indomethacin, but not selective COX-1 or COX-2 inhibitors alone or in combination, reduces survivin expression in gastric mucosal cells and (2) significant reduction of survivin precedes greater severity of gastric injury.

AB - Background & Aims: Nonsteroidal anti-inflammatory drugs (NSAIDs) cause gastrointestinal erosions and ulcers. Apoptosis is one of the mechanisms. The role of survivin, an antiapoptosis protein, in NSAID-induced gastric injury is unknown. We examined the role of survivin in NSAID-induced gastric mucosal and gastric cell injury. Methods: We examined: (1) the effects of indomethacin (nonselective NSAID), celecoxib and NS-398 (cyclooxygenase [COX]-2-selective NSAIDs), SC-560 (a COX-1-selective NSAID), and SC-560 plus celecoxib on survivin expression and extent of injury in rat gastric mucosa; (2) the effects of indomethacin, NS-398, SC-560, and SC-560 plus NS-398 on survivin expression and injury in gastric epithelial (RGM-1) cells; and (3) the effects of survivin suppression with small interfering RNA (siRNA) on RGM-1 cell integrity at baseline and following indomethacin injury. Results: Indomethacin treatment dose-dependently reduced survivin protein levels and caused severe injury of gastric mucosa and RGM-1 cells. Suppression of survivin expression with siRNA in RGM-1 cells caused cell damage and increased susceptibility to injury by indomethacin. Celecoxib treatment caused exfoliation of the mucosal surface epithelium, but neither caused deep erosions or altered survivin expression. Neither NS-398 nor SC-560 treatment altered survivin levels or produced injury in vivo or in vitro. COX-1 and COX-2 inhibitor combination caused injury in vivo and in vitro but did not decrease survivin expression. Conclusions: (1) Indomethacin, but not selective COX-1 or COX-2 inhibitors alone or in combination, reduces survivin expression in gastric mucosal cells and (2) significant reduction of survivin precedes greater severity of gastric injury.

UR - http://www.scopus.com/inward/record.url?scp=11144303461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144303461&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2004.10.008

DO - 10.1053/j.gastro.2004.10.008

M3 - Article

VL - 128

SP - 63

EP - 73

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 1

ER -